| Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus–coinfected patients with compensated cirrhosis JA Mira, A Rivero-Juárez, LF López-Cortés, JA Girón-González, F Téllez, ... Clinical Infectious Diseases 56 (11), 1646-1653, 2013 | 112 | 2013 |
| Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory P Tonnerre, D Wolski, S Subudhi, J Aljabban, RC Hoogeveen, ... Nature immunology 22 (8), 1030-1041, 2021 | 70 | 2021 |
| Early transcriptional divergence marks virus-specific primary human CD8+ T cells in chronic versus acute infection D Wolski, PK Foote, DY Chen, LL Lewis-Ximenez, C Fauvelle, J Aneja, ... Immunity 47 (4), 648-663. e8, 2017 | 62 | 2017 |
| Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load K Neukam, A Camacho, A Caruz, N Rallón, A Torres-Cornejo, ... Journal of hepatology 56 (4), 788-794, 2012 | 55 | 2012 |
| Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients K Neukam, JA Mira, J Ruiz-Morales, A Rivero, A Collado, ... Journal of antimicrobial chemotherapy 66 (11), 2605-2614, 2011 | 35 | 2011 |
| Evolution of the innate and adaptive immune response in women with acute Zika virus infection P Tonnerre, JG Melgaço, A Torres-Cornejo, MA Pinto, C Yue, J Blümel, ... Nature microbiology 5 (1), 76-83, 2020 | 28 | 2020 |
| Risk of Liver Decompensation Among HIV/Hepatitis C Virus–Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy J Macías, M Márquez, F Téllez, D Merino, P Jiménez-Aguilar, ... Clinical infectious diseases 57 (10), 1401-1408, 2013 | 27 | 2013 |
| Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients LF Lopez-Cortes, R Ruiz-Valderas, E Sánchez-Rivas, A Lluch, ... Antimicrobial agents and chemotherapy 57 (8), 3746-3751, 2013 | 25 | 2013 |
| Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients S Corchado, LF Lopez-Cortes, A Rivero-Juarez, A Torres-Cornejo, ... PLoS One 9 (7), e101760, 2014 | 24 | 2014 |
| Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy OJ BenMarzouk-Hidalgo, A Torres-Cornejo, A Gutierrez-Valencia, ... Medicine 94 (17), e781, 2015 | 20 | 2015 |
| Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients A Gutierrez-Valencia, A Torres-Cornejo, OJ BenMarzouk-Hidalgo, ... Antiviral therapy 19 (5), 443-447, 2014 | 18 | 2014 |
| Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy A Torres-Cornejo, OJ BenMarzouk-Hidalgo, A Gutiérrez-Valencia, ... AIDS 28 (2), 201-208, 2014 | 17 | 2014 |
| CD4+ T cell restoration and control of hepatitis C virus replication after childbirth SL Coss, A Torres-Cornejo, MR Prasad, M Moore-Clingenpeel, A Grakoui, ... The Journal of clinical investigation 130 (2), 748-753, 2020 | 16 | 2020 |
| Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract A Torres-Cornejo, OJ BenMarzouk-Hidalgo, P Viciana, B Sánchez, ... Clinical Microbiology and Infection 22 (1), 98. e7-98. e10, 2016 | 13 | 2016 |
| Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients A Gutiérrez-Valencia, R Martin-Peña, A Torres-Cornejo, R Ruiz-Valderas, ... Journal of antimicrobial chemotherapy 67 (3), 681-684, 2012 | 13 | 2012 |
| Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir A Gutierrez-Valencia, R Ruiz-Valderas, A Torres-Cornejo, P Viciana, ... Clinical infectious diseases 58 (2), 268-273, 2014 | 12 | 2014 |
| Hurdles to the development of effective HBV immunotherapies and HCV vaccines A Torres-Cornejo, GM Lauer Pathogens & immunity 2 (1), 102, 2017 | 11 | 2017 |
| Immune activation throughout a boosted darunavir monotherapy simplification strategy OJ BenMarzouk-Hidalgo, A Torres-Cornejo, A Gutierrez-Valencia, ... Clinical Microbiology and Infection 20 (12), 1297-1303, 2014 | 11 | 2014 |
| The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype A Rivero-Juarez, LF Lopez-Cortes, A Camacho, A Caruz, ... AIDS 27 (12), 1941-1947, 2013 | 10 | 2013 |
| Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients LF López-Cortés, R Ruiz-Valderas, L Jimenez-Jimenez, ... PloS one 7 (1), e28115, 2012 | 9 | 2012 |
